Pfizer released full tafamidis data demonstrating a 30% reduction (29.5% vs 42.9%) in the risk of all-cause mortality and a 32% reduction in CV-related hospitalizations. The market has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback